Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2017-06-22 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
监事会关于限制性股票激励计划激励对象人员名单的核查意见及公示情况说明
Governance Information Classification · 95% confidence The document is a statement from the Supervisory Board of Kunming Pharmaceutical Corporation regarding the verification and public disclosure of the list of incentive recipients under a restricted stock incentive plan. It discusses compliance with regulatory requirements, internal public notices, and verification of eligibility of incentive recipients. The content focuses on governance and compliance related to a stock incentive plan rather than financial results, audit opinions, or capital changes. It is not a financial report, earnings release, or capital update. It is also not a proxy solicitation or voting result announcement. The document is a governance-related disclosure about stock incentive plan participants and their compliance with relevant laws and regulations. Therefore, the most appropriate classification is Governance Information (CGR). The document length is short and does not contain financial data or audit opinions, so it is not an Annual Report or Audit Report. Confidence is high due to clear governance and compliance content related to stock incentive plans.
2017-06-22 Chinese
2017年第三次临时股东大会的法律意见
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the convening, attendance, voting procedures, and results of a specific shareholders' meeting (the 2017 third extraordinary general meeting) of Kunming Pharmaceutical Group Co., Ltd. It details the legality and validity of the meeting and resolutions passed, including share repurchase and investment partnership establishment. The document is not the meeting materials themselves, nor is it a voting result announcement or a proxy solicitation. It is a legal opinion related to the shareholders' meeting, which is a type of legal proceedings update. Given the nature and content, this fits best under Legal Proceedings Report (LTR). The document length is short and it is not a report publication announcement or certification letter, so those are excluded.
2017-06-20 Chinese
2017年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at an extraordinary shareholders meeting (临时股东大会) held on June 20, 2017. It includes voting results on various proposals, such as share repurchase plans and authorization for the board to handle related matters. The document contains detailed voting statistics and legal attestations from lawyers confirming the legality and validity of the meeting and resolutions. This type of document is a formal announcement of voting results from a shareholders meeting, not a full report or financial statement. It fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4122 characters, which is sufficient for a detailed voting results announcement but not a full report like an annual or interim report. Therefore, the classification is DVA with high confidence.
2017-06-20 Chinese
2017年第三次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2017 Third Extraordinary General Meeting of Shareholders" of KPC Pharmaceuticals, Inc. It contains detailed meeting agenda, voting procedures, and specific proposals to be voted on, including share repurchase and establishment of an investment partnership. The content is focused on the meeting itself, including instructions, agenda, and detailed proposals for shareholder approval. There is no financial statement or comprehensive financial performance data presented, nor is it a transcript of a call or a report publication announcement. The document is clearly the meeting materials provided to shareholders for the Extraordinary General Meeting (EGM). Given the nature of the document as meeting materials for a shareholders meeting, the appropriate classification is AGM Information (AGM-R).
2017-06-12 Chinese
2017年限制性股票激励计划（草案）
Board/Management Information Classification · 95% confidence The document is titled "2017 年限制性股票激励计划（草案）" which translates to "2017 Restricted Stock Incentive Plan (Draft)". It details a stock incentive plan involving restricted stock awards to company directors, senior management, and key employees. The document includes legal references, plan objectives, management structure, stock source, quantity, allocation, vesting conditions, performance targets, accounting treatment, and adjustment procedures. It is a comprehensive plan document outlining the terms and conditions of a stock-based incentive program. This type of document is neither a financial report (like Annual Report or Interim Report) nor a simple announcement. It is a detailed management-related disclosure about stock incentives for executives and employees, which fits best under Board/Management Information (MANG) as it relates to management compensation and incentive arrangements. The document is lengthy (15,000 characters) and contains substantive content, not just an announcement or summary. Therefore, the appropriate classification is MANG with high confidence.
2017-06-02 Chinese
北京德恒（昆明）律师事务所关于昆药集团股份有限公司2017年限制性股票激励计划（草案）的法律意见
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion from a law firm regarding a 2017 restricted stock incentive plan (股权激励计划) for Kunming Pharmaceutical Group Co., Ltd. It includes extensive legal analysis, definitions, qualifications, plan details, stock quantities, pricing, vesting conditions, and accounting treatment related to the stock incentive plan. The document is not a financial report, earnings release, or management discussion, but a legal opinion specifically about the stock incentive plan draft. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes through stock incentives. The document length is substantial and contains substantive content, not just an announcement or certification, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2017-06-01 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.